DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma
Forough Alemi, Faezeh Malakoti, Mostafa Vaghari‐Tabari, Jafar Soleimanpour, Nazila Shabestani, Aydin Raei Sadigh, Nafiseh Khelghati, Zatollah Asemi, Yasin Ahmadi, Bahman Yousefi
Abstract
Osteosarcoma (OS) is the most common bone malignancy that occurs most often in young adults, and adolescents with a survival rate of 20% in its advanced stages. Nowadays, increasing the effectiveness of common treatments used in OS has become one of the main problems for clinicians due to cancer cells becoming resistant to chemotherapy. One of the most important mechanisms of resistance to chemotherapy is through increasing the ability of DNA repair because most chemotherapy drugs damage the DNA of cancer cells. DNA damage response (DDR) is a signal transduction pathway involved in preserving the genome stability upon exposure to endogenous and exogenous DNA-damaging factors such as chemotherapy agents. There is evidence that the suppression of DDR may reduce chemoresistance and increase the effectiveness of chemotherapy in OS. In this review, we aim to summarize these studies to better understand the role of DDR in OS chemoresistance in pursuit of overcoming the obstacles to the success of chemotherapy.